EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
暂无分享,去创建一个
Stefan Störk | Lale Tokgözoğlu | Philippe Amouyel | Dirk De Bacquer | Zlatko Fras | Jan Bruthans | Andrzej Pajak | Seppo Lehto | Peter Heuschmann | David Moore | Aleksandras Laucevicius | J. De Sutter | P. Heuschmann | P. Amouyel | G. De Backer | J. Deckers | D. De Bacquer | K. Kotseva | D. Wood | S. Lehto | R. Cífková | A. Pająk | S. Störk | J. Goudevenos | C. Jennings | A. Erglis | Ž. Reiner | D. Lovic | N. Gotcheva | Z. Fras | N. Pogosova | L. Rydén | J. Bruthans | V. Gyberg | A. Castro Conde | M. Dilić | M. Dolzhenko | D. Gaita | A. Laucevičius | D. Miličić | D. Moore | E. Nicolaides | R. Oganov | M. Stagmo | L. Tokgözoğlu | D. Vulić | Jaap W Deckers | Andrejs Erglis | Guy De Backer | Zeljko Reiner | Kornelia Kotseva | Johan De Sutter | Dan Gaita | Nana Pogosova | Lars Rydén | Catriona Jennings | Almudena Castro Conde | Mirza Dilic | Nina Gotcheva | Dragan Lovic | Dusko Vulic | David Wood | Viveca Gyberg | Renata Cífková | Maryna Dolzhenko | John Goudevenos | Davor Miličić | Evagoras Nicolaides | Raphael Oganov | Martin Stagmo | D. Vulic
[1] J. Critchley,et al. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.
[2] O. Faergeman,et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial , 2008, The Lancet.
[3] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[4] Ross T Tsuyuki,et al. A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.
[5] Massimo F. Piepoli,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2017, International Journal of Behavioral Medicine.
[6] S. Yusuf,et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.
[7] L. Tavazzi,et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. , 2008, Archives of internal medicine.
[8] Jeroen J. Bax,et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.
[9] K. Kotseva,et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries , 2009, The Lancet.
[10] David R. Wood,et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.
[11] D. Cook,et al. Effect of Smoking Cessation on Mortality After Myocardial Infarction , 2016 .
[12] G. De Backer,et al. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. , 2012, European Heart Journal.
[13] Lisa Hartling,et al. Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease , 2005, Annals of Internal Medicine.
[14] Peter Lindgren,et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .
[15] Shah Ebrahim,et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .
[16] S. Ebrahim,et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.
[17] The Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes , 2009, Diabetologia.
[18] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[19] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.
[20] L. Rydén,et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. , 2006, European heart journal.
[21] P Michael Ho,et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. , 2008, American heart journal.
[22] Bengt Jönsson,et al. [Guidelines on diabetes, pre-diabetes, and cardiovascular diseases]. , 2007, Revista espanola de cardiologia.
[23] Deepak L. Bhatt,et al. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry , 2008, European heart journal.
[24] Ian Graham,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.
[25] F. Palace,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001 .
[26] N J Wald,et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.
[27] S. Galea,et al. Participation rates in epidemiologic studies. , 2007, Annals of epidemiology.
[28] David R Thompson,et al. Exercise-based cardiac rehabilitation for coronary heart disease. , 2016, The Cochrane database of systematic reviews.
[29] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[30] S. Yusuf,et al. Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes , 2010, Circulation.
[31] Jiang He,et al. Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes , 2009, Annals of Internal Medicine.
[32] D. Cook,et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. , 2000, Archives of internal medicine.
[33] C. Morrison,et al. Waist circumference as a measure for indicating need for weight management , 1995, BMJ.
[34] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[35] C. Held,et al. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study , 2013, European journal of preventive cardiology.
[36] D. Alter,et al. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.
[37] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.
[38] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice , 1994 .
[39] A. Morice,et al. Breath carbon monoxide as an indication of smoking habit. , 2000, Chest.
[40] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .
[41] K. Kotseva,et al. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey , 2013, European journal of preventive cardiology.
[42] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[43] A. Hoes,et al. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. , 2014, European heart journal.
[44] S. Yusuf,et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). , 2005, Bulletin of the World Health Organization.
[45] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.
[46] T. Ivanova,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2016 .
[47] K. Kotseva,et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[48] Marcus R. Munafo,et al. Smoking cessation interventions for hospitalized smokers: a systematic review. , 2008, Archives of internal medicine.
[49] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[50] Philippe Amouyel,et al. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .
[51] Wei Li,et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. , 2013, JAMA.
[52] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[53] Roberto Ferrari,et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.
[54] EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. , 1997, European heart journal.